Cancer- and immune-focused drug developers are dominating early-stage venture capital funding so far in 2026, accounting for more than 40% of both the number of biotech companies and total capital raised, according to BioPharma Dive data. The funding concentration highlights continued investor preference for therapeutics in oncology and immune-mediated diseases. For founders and pipeline teams, the headline signal is that capital allocation is skewing toward disease areas where late-stage benchmarks and biomarker development pathways may be perceived as more established. The data also implies that diversification across other modalities and less crowded indications may require clearer differentiation in science, targets, or patient segmentation.